Analysis And Data Insight News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Analysis and data insight. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Analysis And Data Insight Today - Breaking & Trending Today

China's investigator trials accelerate competitive CAR T development

China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. ....

Legend Biotech Corp , Juventas Cell Therapy Ltd , Wuxi Apptec Co , Juno Therapeutics Inc , Pharmaceuticals Inc , Nanjing Legend Biotech Corp , Juno Therapeutics , Wuxi Apptec , Juventas Cell Therapy , Johnson Amp , Nanjing Legend Biotech Co , Juno Therapeutics Inc , Wuxi Apptec Co Ltd , Casi Pharmaceuticals Inc , Juventas Cell Therapy Ltd , Asia Pacific , Car T , Analysis And Data Insight , Deals Andm Amp A , Bioworld Asia ,

Move over, Humira, there's a new mega-blockbuster in town

There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster drug. Not anymore. That title now belongs to Novo Nordisk A/S’ semaglutide, approved as Ozempic in 2017 to treat diabetes and as Wegovy in 2021 to help with weight loss. ....

Novo Nordisk , Merck Co , Novo Nordiska S , Merck Amp Co Inc , Abbvie Inc , Eli Lilly And Co , Teva Pharmaceutical Industries Ltd , Gilead Sciences Inc , Drug Prices , Analysis And Data Insight , Endocrine Metabolic ,

With Bristol Myers' latest cuts, biopharma layoffs reach 7,800+

After investing $24 billion in three major acquisitions earlier this year, Bristol Myers Squibb Co. said April 25 it would cut 2,200 employees and discontinue 12 programs in an effort to save $1.5 billion and put the company on track for growth by the end of the decade. The number of jobs lost represent 28% of all biopharma jobs lost so far in 2024 – 7,834, as announced by 82 companies. There were 17,424 jobs lost at 185 companies in 2023 and 18,500 jobs lost at 123 companies in 2022, according to BioWorld data. ....

Bristol Myers Squibb Co , Bristol Myers Squibb , Bristol Myers Squibb Co , Workforce Reductions , Analysis And Data Insight ,

China's investigator trials accelerate competitive CAR T development

China’s CAR T market is expected to grow from $72 million in 2022 to $342 million over the next decade. There are currently more than 400 CAR T therapies in the pipeline in China, and most of these are being developed by specialized Chinese biotechs. Research by Clarivate plc, BioWorld’s parent company, indicates that a notable proportion of CAR T-cell therapies in late-phase development in China are being developed through strategic partnerships and joint ventures between multinational corporations and domestic companies, including Johnson & Johnson and Nanjing Legend Biotech Corp., Juno Therapeutics Inc. and Wuxi Apptec Co. Ltd., and CASI Pharmaceuticals Inc. and Juventas Cell Therapy Ltd. ....

Wuxi Apptec Co , Juventas Cell Therapy Ltd , Pharmaceuticals Inc , Juno Therapeutics Inc , Legend Biotech Corp , Nanjing Legend Biotech Corp , Juno Therapeutics , Wuxi Apptec , Juventas Cell Therapy , Johnson Amp , Nanjing Legend Biotech Co , Juno Therapeutics Inc , Wuxi Apptec Co Ltd , Casi Pharmaceuticals Inc , Juventas Cell Therapy Ltd , Asia Pacific , Car T , Analysis And Data Insight , Deals Andm Amp A ,